Detalhe da pesquisa
1.
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.
Blood
; 143(16): 1646-1655, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142448
2.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Blood
; 141(6): 567-578, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399715
3.
Loss of BRD4 induces cell senescence in HSC/HPCs by deregulating histone H3 clipping.
EMBO Rep
; 24(10): e57032, 2023 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37650863
4.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet
; 401(10373): 269-280, 2023 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709073
5.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood
; 139(19): 2931-2941, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007321
6.
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268448
7.
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.
Ann Hematol
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662203
8.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Value Health
; 27(5): 607-613, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311180
9.
Top advances of the year: Myeloproliferative neoplasms.
Cancer
; 129(23): 3685-3691, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37768996
10.
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
Cancer
; 129(11): 1681-1690, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36840971
11.
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Cancer
; 129(15): 2321-2330, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042080
12.
Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms.
Cancer Invest
; : 1-20, 2023 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36862101
13.
Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms.
Cancer Invest
; 41(5): 423-431, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883674
14.
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
Haematologica
; 108(10): 2730-2742, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37165840
15.
New Treatments for Myelofibrosis.
Curr Treat Options Oncol
; 24(2): 61-75, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36640223
16.
IMPROVING DIVERSE PARTICIPATION IN CANCER CLINICAL TRIALS.
Trans Am Clin Climatol Assoc
; 133: 149-156, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37701595
17.
Perceptions of patient disease burden and management approaches in systemic mastocytosis: Results of the TouchStone Healthcare Provider Survey.
Cancer
; 128(20): 3700-3708, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35996871
18.
Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey.
Cancer
; 128(20): 3691-3699, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35996873
19.
Defining disease modification in myelofibrosis in the era of targeted therapy.
Cancer
; 128(13): 2420-2432, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35499819
20.
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Br J Haematol
; 198(2): 317-327, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35476316